Rezolute, Inc.

NEWS

Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

March 25, 2022

10 min read

Mark Terry

Business

BioSpace Movers & Shakers, March 12

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

March 11, 2021

7 min read

Alex Keown

JOBS

IN THE PRESS

Press Releases

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025

5 min read

Press Releases

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 14, 2025

7 min read

Press Releases

Rezolute to Participate in Upcoming Investor Conferences - May 1, 2025

May 2, 2025

1 min read

Press Releases

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

April 23, 2025

6 min read

Press Releases

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

March 27, 2025

3 min read

Press Releases

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 12, 2025

7 min read

Press Releases

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

January 31, 2025

1 min read

Press Releases

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 8, 2025

6 min read

Press Releases

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2024

December 6, 2024

3 min read

Press Releases

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

December 4, 2024

5 min read